Doximity Stock News

Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.

Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.

Healthcare is sometimes viewed as a defensive sector in uncertain times.

Investors were happy with the third-quarter earnings report.

Investors were happy with the third-quarter earnings report.

Don't overlook these potentially huge tech trends.

Healthcare is the smart play in this bear market. Here''s why these three Fool.com contributors like Doximity, Amgen, and Novocure.

Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.

These two companies are unsung heroes in their markets, and that could mean they are undervalued today.

Monday''s top analyst upgrades and downgrades included Chewy, Cloudflare, Coca-Cola, Doximity, Ideanomics, GlaxoSmithKline, Micron Technology, SoFi Technologies, Teladoc Health, Twitter and Walmart.

Patient investors who buy this unique healthcare stock now could see market-beating returns.

Doximity announced financial results that make its long-term future look bright.

Doximity announced financial results that make its long-term future look bright.

Doximity Inc - Class A (DOCS) shares closed this week 32.0% higher than it did at the end of last week. The stock is currently up 20.3% year-to-date, up 13.8% over the past 12 months, and up 13.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $64.95 and as low as $44.65 this week.Shares closed 47.7% below its 52-week high and 41.2% above its 52-week low.Trading volume this week was 42.5% higher than the 10-day average and 121.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -5765.5% The company's stock price performance over the past 12 months beats the peer average by -205.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Goldman Sachs has initiated Teladoc and Doximity with buy ratings as the firm has a positive view on the healthcare technology sector for the long term.